Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man

J Hum Hypertens. 1989 Aug;3(4):267-70.

Abstract

Little is known of the significance of perivascular peptides in hypertension. In this study we have investigated the circulating levels of calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) and substance P- like immunoreactivity (SP-LI) during and after treatment of severe hypertension. Seventeen patients with a mean blood pressure of 204/127 mmHg were included. Circulating levels of CGRP-LI and SP-LI in normotensive controls were 35 +/- 4 and 1.2 +/- 0.1 pmol/l, respectively. In the hypertensives CGRP-LI was significantly lower (22 +/- 3 pmol/l: P less than 0.05) while SP-LI did not differ (1.6 +/- 0.3 pmol/l) from the normotensives. After treatment the circulating level of CGRP-LI was still significantly lower (16 +/- 2 pmol/l: P less than 0.001) while SP-LI remained unchanged when compared with the controls. These observations suggest an involvement of vascular afferent nerves in the aetiology of hypertension in man.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Afferent Pathways / physiopathology
  • Aged
  • Blood Pressure
  • Calcitonin Gene-Related Peptide / blood*
  • Calcium Channel Blockers / therapeutic use
  • Diuretics / therapeutic use
  • Female
  • Heart Rate
  • Humans
  • Hypertension / blood*
  • Hypertension / drug therapy
  • Hypertension / physiopathology
  • Male
  • Middle Aged
  • Radioimmunoassay
  • Substance P / blood*

Substances

  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers
  • Diuretics
  • Substance P
  • Calcitonin Gene-Related Peptide